

## Localization, Morphologic Features, and Chemical Composition of Calciphylaxis-Related Skin Deposits in Patients With Calcific Uremic Arteriolopathy

Hester Colboc, Philippe Moguelet, Dominique Bazin, Priscille Carvalho, Anne-Sophie Dillies, Guillaume Chaby, Hervé Maillard, Diane Kottler, Elisa Goujon, Christine Jurus, et al.

### ▶ To cite this version:

Hester Colboc, Philippe Moguelet, Dominique Bazin, Priscille Carvalho, Anne-Sophie Dillies, et al.. Localization, Morphologic Features, and Chemical Composition of Calciphylaxis-Related Skin Deposits in Patients With Calcific Uremic Arteriolopathy. JAMA Dermatology, 2019, 155 (7), pp.789-796. 10.1001/jamadermatol.2019.0381. hal-02291277

## HAL Id: hal-02291277 https://hal.sorbonne-universite.fr/hal-02291277v1

Submitted on 18 Sep 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés. 1 Original Investigation

# Localization, Morphology and Chemical Composition of Calciphylaxis-Related Skin Deposits

4 Running head: Characterization of calciphylaxis-related skin deposits

5 Manuscript word count: 2902/3000; Table count: 1; Figure count: 4

- 6 Online supplement: eTable 1
- 7

Hester Colboc, MD; Philippe Moguelet, MD;\* Dominique Bazin, MD;\* Priscille Carvalho,
MD; Anne-Sophie Dillies, MD; Guillaume Chaby, MD; Hervé Maillard, MD; Diane Kottler,
MD; Elisa Goujon, MD; Christine Jurus, MD; Marine Panaye, MD; Vincent Frochot, MD;
Emmanuel Letavernier, MD, PhD; Michel Daudon, MD; Ivan Lucas, MD; Raphaël Weil,
MD; Philippe Courville, MD; Jean-Benoit Monfort, MD; François Chasset, MD; Patricia
Senet, MD; on behalf of the Groupe Angio-Dermatologie of the French Society of
Dermatology

15

Author Affiliations: Sorbonne Université, Hôpital Rothschild, Service Plaies et Cicatrisation, 16 Paris (Colboc); Sorbonne Université, Hôpital Tenon, Anatomie et Cytologie Pathologiques, 17 Paris, (Moguelet); CNRS, Laboratoire de Chimie Physique, Ba340, Université Paris XI, 18 19 91405 Orsay (Bazin); Centre Hospitalier Universitaire de Rouen, Service de Dermatologie, Rouen (Carvalho); Centre Hospitalier Universitaire d'Amiens, Service de Dermatologie, 20 Amiens (Dillies, Chaby); Centre Hospitalier du Mans, Service de Dermatologie, Le Mans 21 22 (Maillard); Hôpital Bichat, Service de Dermatologie, Paris (Kottler); Centre Hospitalier de Chalon-sur-Saône, Service de Dermatologie, Chalon-sur-Saône (Goujon); Clinique du 23 Tonkin, Service de Médecine Vasculaire, Villeurbanne (Jurus, Panaye); Sorbonne Université, 24 25 Hôpital Tenon, Service des Explorations Fonctionnelles Multidisciplinaires, Paris (Frochot,

| 26 | Letavernier, Daudon); Sorbonne Universités, UMR 8235, Paris (Lucas); CNRS, LPS, Ba510, |
|----|--|
| 27 | Université Paris XI, 91405 Orsay (Weil); Centre Hospitalier Universitaire de Rouen,    |
| 28 | Anatomie et Cytologie Pathologiques, Rouen (Courville); Sorbonne Université, Hôpital   |
| 29 | Tenon, Service de Dermatologie, Paris (Monfort, Chasset, Senet)-all in France.         |
| 30 | *These authors contributed equally to this work.                                       |
| 31 |  |
| 32 | Corresponding Author: Dr Hester Colboc, APHP, Service Plaies et Cicatrisation, Hôpital |
| 33 | Rothschild, 5, Rue Santerre, 75012 Paris, France. Phone: +33 (0)6 03 61 16 23;         |
| 34 | (hester.colboc@aphp.fr)  |
| 35 |  |
| 36 | Funding sources: None  |
| 37 | Conflicts of interest: None declared   |
| 38 | Word count: 2902/3000  |
| 39 |  |
| 40 |  |
| 41 |  |
| 42 |  |
| 43 |  |
| 44 |  |
| 45 |  |
| 46 |  |
| 47 |  |
| 48 |  |
| 49 |  |
|    |  |

#### 51 Key Points

**Question** What are the precise localization, morphology and chemical composition of 53 calciphylaxis-related skin deposits?

Findings CUA calcifications are composed of pure calcium–phosphate apatite, always located circumferentially, mostly in the intima of otherwise normal-looking vessels, and often associated with interstitial deposits, unlike calcifications observed in cutaneous arteriolosclerotic vessels, which are associated with medial hypertrophy containing the calcifications and no interstitial deposits.

**Meaning** The differences observed between CUA and cutaneous arteriolosclerosis regarding 60 calcification location and vessel morphology suggest different pathogenetic mechanisms and 61 provide new insights into CUA pathogenesis that could explain the poor efficacy of 62 vasodilators and the therapeutic effect of calcium-solubilizing drugs.

76 **Abstract** 311/350

**IMPORTANCE** Calcific uremic arteriolopathy (CUA), a rare disease with calcium deposits
 in skin, mostly affects dialyzed, end-stage renal disease patients. Chemical composition and
 structure of CUA calcifications have been poorly described.

80 **OBJECTIVES** To describe the localization and morphology, determine the precise chemical

composition of CUA-related calcium deposits in skin, and identify any mortality-associatedfactors.

**DESIGN** A retrospective, multicenter case control study was conducted between January
2006 and January 2017.

85 **SETTING** Seven French hospitals participated in the study.

PARTICIPANTS This study included consecutive adults diagnosed with CUA, confirmed according to Hayashi's clinical and histologic criteria. Patients with normal renal function were excluded. For comparison, 5 skin samples from patients with arteriolosclerosis and 5 others from the negative margins of skin-carcinoma resections were also analyzed.

90 MAIN OUTCOME(S) AND MEASURE(S) Localization and morphology of the CUA-91 related cutaneous calcium deposits were assessed with optical microscopy and field-92 emission–scanning electron microscopy (FE-SEM), and the chemical compositions of those 93 deposits were evaluated with µFourier transform infra-red (FT-IR) spectroscopy, Raman 94 spectroscopy and energy dispersive X-ray (EDX).

95 RESULTS Thirty-six patients (median age: 64 years) were included, and 29 cutaneous 96 biopsies were analyzed. CUA and arteriolosclerosis skin calcifications were composed of pure 97 calcium–phosphate apatite. CUA vascular calcifications were always circumferential, found 98 in small-to-medium–sized vessels, with interstitial deposits in 76% of the samples. A 99 thrombosis, most often in noncalcified capillary lumens in the superficial dermis, was seen in 5 CUA patients' samples. Except for calcium deposits, CUA patients' vessel structure appeared normal, unlike thickened arteriolosclerotic vessel walls. Twelve (33%) patients diedof CUA.

**CONCLUSIONS AND RELEVANCE** CUA-related skin calcifications were exclusively 104 composed of pure calcium–phosphate apatite, localized circumferentially in small-to-105 medium–sized vessels and often associated with interstitial deposits, suggesting its 106 pathogenesis differs from that of arteriolosclerosis. Although the chemical compositions of 107 CUA and arteriolosclerosis calcifications were similar, the vessels' appearances and deposit 108 localizations differed, suggesting different pathogenetic mechanisms.

#### 123 Introduction

Uremic calciphylaxis, also called calcific uremic arteriolopathy (CUA), is a rare and severely 124 morbid condition that predominantly affects dialyzed, end-stage renal disease (ESRD) 125 patients. Its frequency among ESRD patients reaches 4% and its incidence increases for those 126 on hemodialysis.<sup>1</sup> CUA's significant morbidity and mortality result from extensive skin 127 necrosis and septic complications, with the latter being the leading cause of death. For ESRD 128 patients, an increased risk of subsequent CUA development has been associated with female 129 sex, diabetes mellitus, higher body mass index, elevated serum calcium, phosphorus and 130 parathyroid hormone levels, nutritional status einacalcet or vitamin K-antagonist treatments.<sup>2</sup> 131

Although noninvasive imaging tools (eg, plain X-rays) have been reported to help diagnose CUA,<sup>3</sup> none of those tools have been systematically evaluated.<sup>4</sup> Definitive CUA diagnosis requires a skin biopsy. However, because biopsying the skin is associated with the risk of new ulceration, bleeding and infection, actually obtaining one is often discussed sometimes debated.<sup>5</sup> When obtained, deep cutaneous biopsies of CUA lesions show smallsized calcifications, <500  $\mu$ m, in hypodermal vessels and/or interstitial tissue, highly suggestive of CUA with good specificity.<sup>6</sup>

Despite well-characterized clinical and histologic descriptions of CUA, its precise pathogenetic mechanism remains unclear.<sup>7</sup> Arteriolar calcification is probably the first event, followed by thrombosis and skin ischemia. Chemical composition determination and description of the skin calcifications through physicochemical techniques could contribute to understanding CUA pathogenesis, leading to more appropriate and specific treatments.<sup>8</sup> Indeed, nanotechnologies are receiving increased attention to improve understanding of the effects of pathologic deposits on living tissues.<sup>9,10</sup>

146 The aims of this study were to determine precisely the localization, morphology and 147 chemical composition of calcifications in the skin of CUA patients, and then examine whether any association could be established between their microscopy findings and clinicalcharacteristics.

150

#### 151 Methods

This study was conducted in compliance with Good Clinical Practices and the Declaration of
Helsinki, and in accordance with French law. Formal Ethics Committee approval of the study
protocol was obtained (no. EudraCT 2017-000906-39).

155

#### 156 Case Selection and Histopathologic Analyses

This retrospective <u>case control</u> study included consecutive adults diagnosed with CUA, confirmed according to Hayashi's clinical and histologic criteria, and seen in 7 French hospitals between January 2006 and January 2017.<sup>11</sup> Patients with normal renal function were excluded. Patients' medical histories, treatments and laboratory findings were extracted from their medical charts. They were classified into 2 clinical subgroups, distal or proximal CUA, according to the skin-lesion localizations described by Brandenburg et al.<sup>12</sup>

Five skin samples from patients with arteriolosclerosis and 5 others from the negative margins of skin carcinoma resections on the leg were included and served as controls. All 10 controls had normal renal function; only the 5 with arteriolosclerosis from among a cohort of patients with necrotic angiodermatitis had leg-skin biopsies.

Skin-biopsy samples were sent to and centralized in Tenon Hospital, Department of
Pathology. For each subject, 1.5-μm–thick sections of paraffin-embedded skin biopsies were
deposited on glass slides, for hematoxylin–eosin–saffron (HES) and von Kossa staining, and
low-e microscope slides (MirrIR, Kevley Technologies, Tienta Sciences, Indianapolis, IN,
USA) for field-emission–scanning electron microscopy (FE-SEM), μFourier transform infrared (FT-IR) spectroscopy and Raman spectroscopy.<sup>13</sup> Vascular and interstitial calcifications,

the calibers of calcified vessels and the topography of deposits in skin sections were analyzedand compared between CUA patients and controls.

175

#### 176 **FE-SEM**

FE-SEM (Zeiss SUPRA55-VP, Oberkochen, Germany) was used to describe the
ultrastructural characteristics of tissue sections. As previously described, high-resolution
images were obtained with in-lens and Everhart-Thornley secondary electron detectors.<sup>14</sup>
Measurements were taken at low voltage (1–2 kV), without the usual carbon-coating of the
sample surface. For some samples, energy-dispersive X-ray (EDX) was also used to identify
calcium in the abnormal deposits.

183

#### 184 FT-IR and Raman Spectroscopies

Using the same sample as that for FE-SEM analyses, FT-IR and Raman spectroscopies 185 186 identified the chemical compositions of the CUA calcifications. All the FT-IR hyperspectral images were recorded with a Spectrum Spotlight 400 FT-IR imaging system (Perkin-Elmer 187 Life Sciences, Courtaboeuf, France), with 6.25-mm spatial resolution and 8-cm<sup>-1</sup> spectral 188 resolution.<sup>16</sup> Raman spectra were collected with a micro-Raman system (LabRam HR-800 189 Evolution, Horiba, Japan) using 785-nm laser excitation wavelength, 100× objective 190 191 (Olympus, numerical aperture 0.9) and 300 grooves per mm grating. Spectra were corrected at baseline to suppress the strong luminescence background.<sup>15</sup> 192

193

#### 194 Statistical Analyses

Data are expressed as median [range] or number (%).  $\chi^2$  or Fisher's exact tests were used to compare qualitative variables; Wilcoxon or Mann–Whitney tests were used to compare paired or nonpaired nonnormally distributed variables, respectively. Parameters with P < .2 in univariate analysis were entered into a multivariate logistic-regression model, with *Y* as thedependent variable.

200

#### 201 **Results**

#### 202 Clinical and Histopathologic Findings

Among the 36 CUA patients included, 29 skin biopsies could be analyzed by optical microscopy, FE-SEM and spectroscopies. Clinical and histopathologic data are summarized in Table 1.

Optical microscopy analysis of HES- and von Kossa-stained CUA biopsies always found calcifications in small-and/or-medium–sized vessels (diameter: 10–300 µm), mostly in hypodermal arterioles and capillaries (Figure 1). These deposits were massive, occupying in the entire circumference of the vessel, and located in the intima and sometimes the media. They could be associated with intimal fibrous or myxoid changes.

211 Those CUA vascular calcifications were associated with interstitial deposits, mainly localized to the hypodermis, in 76% of the samples. Calcification size ranged from 1 to 500 212 µm, sometimes becoming confluent, with clusters reaching several millimeters in diameter. 213 They were either isolated small clusters between adipocytes (Figure 2A and B) or aligned in a 214 pearl collar along the cytoplasmic membranes of adipocytes (Figure 2D and E). Calcified 215 216 elastic fibers and/or collagen fibers were also seen in hypodermic septa or deep dermis. Thromboses were seen in 5 samples, most often in noncalcified capillaries in the superficial 217 218 dermis.

The 5 arteriolosclerosis-control biopsies showed classical intimal fibrous endarteritis and Monckeberg medial calcinosis associated with calcium deposits that were localized within the media along the internal elastic lamina. Those calcifications were never circumferential and no interstitial localization was observed. Negative margins of resected carcinomas contained 223 no vascular or interstitial calcium deposits.

Twelve (33%) patients died of CUA. Poorer CUA prognosis was only associated with male sex or nodular lesions (eTable 1 in the supplement).

226

#### 227 FE-SEM and EDX Analyses

Subcellular calcification localization and morphology were assessed with FE-SEM. CUA vascular deposits were circumferential (Figures 1F and 2C); at least 1 thrombosis in 5/29 samples was located in the vessel lumen or intima, while the media usually appeared normal with rare calcifications. Interstitial deposits surrounded adipocytes, along the cell membranes. Morphologically, these calcifications appeared to be composed of aggregated micrometric plates (Figure 2F).

FE-SEM analyses of control skin biopsies showing arteriolosclerosis contained vascular calcifications in the media (Figure 1C), associated with medial hypertrophy and intimal fibrosis; no interstitial deposits were seen. FE-SEM analyses of negative resected carcinoma margins confirmed the absence of vascular and interstitial deposits.

EDX analyses of CUA samples verified the calcium and phosphate composition of vascular and interstitial deposits, with similar calcium/phosphate ratios in both sites. EDX analyses showed the composition of vascular deposits in control arteriolosclerosis biopsies to be similar to that found in CUA.

242

#### 243 Spectroscopy Analyses

FT-IR analyses of CUA and arteriolosclerosis skin calcifications showed that all were composed of calcium–phosphate apatite (Figure 3). Careful examination of 3 CUA samples identified the presence of amorphous carbonated calcium–phosphate associated with calcium– phosphate apatite that was not seen in any arteriolosclerosis patients' samples. Raman spectroscopy confirmed the similar calcium–phosphate-apatite compositions of
 vascular and interstitial calcifications (Figure 4).<sup>16</sup>

250

#### 251 **Discussion**

These FE-SEM, EDX and spectroscopy analyses were able to finally specify the localization and the complete chemical composition of CUA patients' skin calcifications. Our spectroscopic analyses demonstrated that those circumferential calcifications, located in the intima and media of CUA patients' skin vessels, were composed exclusively of calcium– phosphate apatite. In 76% of the CUA patients' samples, calcium–phosphate apatite was also found in interstitial tissue of the deep dermis and hypodermis, along the cytoplasmic membranes of adipocytes, and elastic and collagen fibers.

The chemical composition and localization of cutaneous CUA calcifications have been 259 investigated in only a few small series. Using EDX and FE-SEM, Kramann et al found 260 calcium/phosphate accumulations, with a molar ratio matching that of hydroxyapatite, in the 261 hypodermis of 7 CUA patients.<sup>17</sup> Two other studies used mass spectrometry and Raman 262 spectroscopy to detect and characterize CUA skin calcifications. Using mass spectrometry, 263 Amuluru et al showed that tissue samples from 12 CUA patients had high iron and aluminum 264 contents, suggesting a role of metal deposition in CUA pathogenesis.<sup>18</sup> Using 265 266 microcomputed-tomography and Raman spectroscopy, Lloyd et al confirmed the presence carbonated apatite in debrided CUA tissues from 6 patients.<sup>19</sup> However, those studies 267 included only small numbers of samples and performed only chemical analyses. To the best 268 269 of our knowledge, the precise localization and exact morphology of these abnormal deposits have not yet been reported. 270

Patients with proximal lesions, high body mass index, ulcerated lesions and female were
 reported to have poorer prognoses.<sup>20</sup> Our univariate and multivariate analyses did not identify

those factors as having a relationship with shorter survival, and retained only male sex and nodular lesions as being significantly associated with mortality. However, the relatively small number of patients included make those findings less relevant than risk factors identified in larger studies.

277 Skin deposits in CUA and arteriolosclerosis patients were always composed of calcium– 278 phosphate apatite, but their different localizations in the vessel walls could indicate different 279 pathogenetic mechanisms. Indeed, arteriolosclerotic vessel walls are thickened, with media 280 hypertrophy, suggestive of slowly progressive thickening and degeneration of the arteriolar 281 wall with secondary calcium–phosphate apatite accumulation. Circumferential CUA vascular 282 deposits were located mostly in the intima of otherwise normal-looking vessels, suggesting a 283 faster and global process, with primary calcium deposition.

Ellis et al recently showed that pathognomonic cutaneous calcifications associated with 284 CUA could also occur in viable tissue from ESRD patients without CUA, with ESDR 285 amputated because of peripheral arterial disease.<sup>21,22</sup> However, Ellis et al did not consider that 286 some of their controls might have had undiagnosed acral calciphylaxis and undergone 287 amputations for distal ischemia. Those possibilities might explain some of their 288 histopathologic observations of calciphylaxis in their controls. However, Our histologic 289 findings (circumferential calcifications of small-to-medium-sized vessels often associated 290 291 with interstitial calcifications) and high-technology tools, such as FE-SEM, enabled us to demonstrate several differences between the vascular calcifications seen in CUA and 292 arteriolosclerosis, thereby confirming our previous results and those of Chen et al.<sup>6,23</sup> 293

Patients with calciphylaxis probably develop skin calcifications subsequent to a dysequilibrium between calcification promoters and inhibitors. Calcium-inhibitor deficiency, like matrix Gla protein, impaired inhibition of calcium-phosphate precipitation, thereby leading to skin calcifications.<sup>20</sup> 298 Chronic inflammatory states, including ESRD, are associated with increased levels of 299 reactive oxygen species that impair endothelial function.<sup>24</sup> ESRD-related endothelial 300 dysfunction engenders vessel-wall abnormalities, including the presence of bone 301 morphogenetic protein in medial and intimal layers.<sup>25</sup> Such vascular protein modification, 302 associated with increased calcium × phosphate products, might explain the intimal and medial 303 calcifications observed in CUA.

Interstitial calcifications were also seen in 76% of CUA samples. Voluminous 304 calcifications of the subcutaneous tissue or dystrophic and metastatic calcinosis cutis are 305 known to occur in a variety of disorders, including dermatomyositis, lupus or trauma. The 306 ectopic calcified masses, composed of hydroxyapatite and amorphous calcium-phosphate 307 apatite, were disseminated throughout the dermis and hypodermis that appeared petrified, 308 involving interstitial tissue and vessels.<sup>26</sup> The pathophysiology is still unclear but it has been 309 hypothesized that hypodermal inflammation might release the phosphate bound to denatured 310 proteins and serve as a niche for ectopic calcifications.<sup>26</sup> However, despite clinical and 311 pathologic differences, the physiology of these calcifying disorders might be similar, and 312 calcium deposits obstructing some hypodermis vessels in CUA might lead to detrimental 313 adipocyte, collagen and elastic fiber alterations, and the release of the phosphate bound to 314 denatured proteins and ectopic interstitial calcifications. According to that hypothesis, 315 316 interstitial calcifications might be a secondary phenomenon, thereby explaining the inconstant interstitial localization. The constant presence of vascular deposits could suggest a primary 317 vascular trigger of CUA. 318

Our finding that CUA vascular calcifications were always circumferential, suggests that therapeutic strategies with vasodilators might be less relevant than those using calciumsolubilizing drugs. Therefore, drugs directly impacting calcium–phosphate precipitation, like sodium thiosulfate, bisphosphonates and vitamin K supplementation would seem to be more appropriate and a rational approach for future therapeutic studies on CUA.<sup>27,28</sup> Along the
same line, Dedinszki et al, who studied other calcifying disorders, including pseudoxanthoma
elasticum and generalized arterial calcifications of infancy, reported that oral pyrophosphate
inhibited tissue calcifications.<sup>29</sup>

Because our study was retrospective, some information, including vital status was missing for some patients. Our failure to identify factors associated with higher mortality in larger studies might be explained by the relatively small size of our series. It is worth highlighting that calcification morphology can be modified by the sectioning of paraffinembedded skin biopsies and that the appearance of these deposits may differ between glass and low-e slides, making it more difficult to discern the relationship between optical microscopy and electronic microscopy.

334

#### 335 Conclusions

In conclusion, our histologic, FE-SEM, EDX and spectroscopy results provide a better understanding of the morphologic, ultrastructural and chemical characteristics of CUA patients' skin calcium–phosphate-apatite deposits. Those deposits appear to be initially vascular and develop rapidly in normal vessel walls. Circumferential vascular and interstitial deposits, albeit inconstant, were specific to CUA. Although the chemical compositions of the calcifications were similar in CUA and arteriolosclerosis, the vessels' appearances and deposit localizations differed, suggesting different pathogenetic mechanisms.

343

#### 344 Acknowledgments

345 Access to Data and Data Analysis

Hester Colboc had full access to all the data in the study and takes responsibility for theintegrity of the data and the accuracy of the data analysis.

The authors declared no conflicts of interest involving this work, no relevant financial 349 350 activities outside the submitted work (during the 3 years prior to submission) and no other relationships or activities that readers could perceive to have influenced, or that give the 351 appearance of potentially influencing, what is written in the submitted work (based on all 352 353 relationships that were present during the 3 years prior to submission). 354 Funding/Support: no funding. 355 356 Role of Funder/Sponsor Statement 357 358 No funding organization or sponsor we involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or 359 approval of the manuscript; and decision to submit the manuscript for publication. 360 361 The authors thank LabEx MICHEM (ANR-11-IDEX-0004-02) for allowing us to use their 362 nano/micro-Raman facilities in UPMC. We thank Quentin Rezard from CNRS, LPC, Ba340, 363 Université Paris XI, and Chantal Jouanneau from INSERM, Hôpital Tenon, for their help and 364 support in this study 365 366 367 **REFERENCES** 368 Weenig RH, Sewell LD, Davis MD, McCarthy JT, Pittelkow MR. Calciphylaxis: natural 369 1. history, risk factor analysis, and outcome. JAm Acad Dermatol. 2007;56(4):569-579. 370 2. Nigwekar SU, Zhao S, Wenger J, et al. A nationally representative study of calcific 371 372 uremic arteriolopathy risk factors. J Am Soc Nephrol. 2016;27(11):3421-3429.

- 373 3. Shmidt E, Murthy NS, Knudsen JM, et al. Net-like pattern of calcification on plain softtissue radiographs in patients with calciphylaxis. *J Am Acad Dermatol.* 2012;67(6):12961301.
- Halasz CL, Munger DP, Frimmer H, Dicorato M, Wainwright S. Calciphylaxis:
   comparison of radiologic imaging and histopathology. *J Am Acad Dermatol.* 2017;77(2):241-246.
- 379 5. Nigwekar SU, Kroshinksy D, Nazarian RM, et al. Calciphylaxis: risk factors, diagnosis,
  380 and treatment. *Am J Kidney Dis.* 2015;66(1):133-146.
- 381 6. Cassius C, Moguelet P, Monfort JB, et al. Calciphylaxis in haemodialysed patients:
  382 diagnostic value of calcifications in cutaneous biopsy. *Br J Dermatol.* 2018;178(1):292383 293.
- Jean G, Terrat JC, Vanel T, et al. Calciphylaxis in dialysis patients: to recognize and treat
  it as soon as possible. *Nephrol Ther*. 2010;6(6):499-504.
- Bazin D, Daudon M, Combes C, Rey C. Characterization and some physicochemical
   aspects of pathological microcalcifications. *Chem Rev.* 2012;112(10):5092-5120.
- Colboc H, Moguelet P, Bazin D, et al. Physicochemical characterization of inorganic
   deposits associated with granulomas in cutaneous sarcoidosis. *J Eur Acad Dermatol Venereol.* 2019;33(1):198-203.
- Bazin D, Daudon M. Pathological calcifications and selected examples at the medicine–
  solid-state physics interface. *J Phys Appl Phys.* 2012;45(38):383001.
- 393 11. Hayashi M. Calciphylaxis: diagnosis and clinical features. *Clin Exp Nephrol.*394 2013;17(4):498-503.
- 395 12. Brandenburg VM, Cozzolino M, Ketteler M. Calciphylaxis: a still unmet challenge. J
  396 Nephrol. 2011;24(2):142-148.
- 13. Dessombz A, Bazin D, Dumas P, Sandt C, Sule-Suso J, Daudon M. Shedding light on the

- chemical diversity of ectopic calcifications in kidney tissues: diagnostic and research
  aspects. *PloS One*. 2011;6(11):e28007.
- 400 14. Brisset F. *Microscopie Électronique à Balayage et Microanalyses*. Paris, France: EDP
  401 Sciences; 2012.
- 402 15. Carden A, Morris MD. Application of vibrational spectroscopy to the study of
  403 mineralized tissues (review). *J Biomed Opt.* 2000;5(3):259-269.
- 404 16. Awonusi A, Morris MD, Tecklenburg MM. Carbonate assignment and calibration in the
  405 Raman spectrum of apatite. *Calcif Tissue Int.* 2007;81(1):46-52.
- 406 17. Kramann R, Brandenburg VM, Schurgers LJ, et al. Novel insights into osteogenesis and
- 407 matrix remodelling associated with calcific uraemic arteriolopathy. *Nephrol Dial*408 *Transplant*. 2013;28(4):856-868.
- 409 18. Amuluru L, High W, Hiatt KM, et al. Metal deposition in calcific uremic arteriolopathy.
  410 *J Am Acad Dermatol.* 2009;61(1):73-79.
- 411 19. Lloyd WR, Agarwal S, Nigwekar SU, et al. Raman spectroscopy for label-free
  412 identification of calciphylaxis. *J Biomed Opt.* 2015;20(8):80501.
- 413 20. Nigwekar SU, Thadhani R, Brandenburg VM. Calciphylaxis. *N Engl J Med.*414 2018;378(18):1704-1714.
- 21. Ellis CL, O'Neill WC. Questionable specificity of histologic findings in calcific uremic
  arteriolopathy. *Kidney Int.* 2018;94(2):390-395
- 417 22. Nigwekar SU, Nazarian RM. Cutaneous calcification in patients with kidney disease is
  418 not always calciphylaxis. *Kidney Int.* 2018;94(2):244-246.
- 23. Chen TY, Lehman JS, Gibson LE, Lohse CM, El-Azhary RA. Histopathology of
  calciphylaxis; cohort study with clinical correlations. *Am J Dermatopathol*.
  2017;39(11):795-802.
- 422 24. Sowers KM, Hayden MR. Calcific uremic arteriolopathy: pathophysiology, reactive

| 423 | oxygen species and therapeutic approaches. Oxid Med Cell Longev. 2010;3(2):109-121.          |
|-----|--|
| 424 | 25. Nigwekar SU, Jiramongkolchai P, Wunderer F, et al. Increased bone morphogenetic          |
| 425 | protein signaling in the cutaneous vasculature of patients with calciphylaxis. Am $J$        |
| 426 | Nephrol. 2017;46(5):429-438.   |
| 427 | 26. Reiter N, El-Shabrawi L, Leinweber B, Berghold A, Aberer E. Calcinosis cutis: part I.    |
| 428 | Diagnostic pathway. J Am Acad Dermatol. 2011;65(1):1–12.                                     |
| 429 | 27. Zitt E, König M, Vychytil A, et al. Use of sodium thiosulphate in a multi-interventional |
| 430 | setting for the treatment of calciphylaxis in dialysis patients. Nephrol Dial Transplant.    |
| 431 | 2013;28(5):1232-1240.  |
| 432 | 28. Nigwekar SU, Bloch DB, Nazarian RM, et al. Vitamin K-dependent carboxylation of          |
| 433 | matrix Gla protein influences the risk of calciphylaxis. J Am Soc Nephrol.                   |
| 434 | 2017;28(6):1717-1722.  |
| 435 | 29. Dedinszki D, Szeri F, Kozák E, et al. Oral administration of pyrophosphate inhibits      |
| 436 | connective tissue calcification. EMBO Mol Med. 2017;9(11):1463-1470.                         |
| 437 |  |
| 438 |  |
| 439 |  |
| 440 | Figure legends   |
| 441 | Fig 1. Skin biopsy sections. Arteriolosclerosis with asymmetrical fibrous intimal thickening |
| 442 | ("fibrous endarteritis") and Monckeberg medial calcinosis, ie, calcification of the internal |
| 443 | elastic lamina and media: A, hematoxylin-eosin-saffron (HES)-stained (×400); B, von Kossa-   |
| 444 | stained (×400); C, FE-SEM. Calcific uremic arteriolopathy (CUA) hypodermic arterioles with   |
| 445 | voluminous and circumferential parietal calcium deposits: D, HES-stained (×400), E, von      |
| 446 | Kossa-stained (×400); F, FE-SEM.   |
| 447 |  |





450 Fig 2. Skin biopsy sections. CUA hypodermic capillaries with voluminous and
451 circumferential parietal calcium deposits: A, HES-stained (×400), B, von Kossa-stained
452 (×400), C, FE-SEM. Interstitial CUA deposits, aligned along the cytoplasmic membranes of
453 adipocytes: D, HES-stained (×400); E, von Kossa-stained (×400); F, FE-SEM.



Fig 3. μFourier transform infra-red (FT-IR) spectroscopy of the interstitial CUA deposits: A,
Skin biopsy of CUA; B, IR map of the red square area, showing an intense vascular deposit;
C, IR spectrum of this vascular deposit: calcium–phosphate apatite spectrum with
characteristic peaks (1015, 959 and 875 cm<sup>-1</sup>) in a protein matrix (skin tissue). The same
spectrum was obtained for CUA and arteriolosclerosis vascular calcifications.



461

**Fig 4.** Micro-Raman signatures and optical micrographs (magnification 10× and 100×) of A, peri-adipocyte and B, vascular calcifications (excitation wavelength  $\lambda_{exc} = 785$  nm, objective 100×, numerical aperture = 0.9). The Raman bands at 960, 1076 and 590 cm<sup>-1</sup> correspond, respectively, to the v<sub>1</sub>, v<sub>3</sub> and v<sub>4</sub> phosphate vibrations of apatite. The low-intensity v<sub>4</sub> carbonate vibrations around 680–715 cm<sup>-1</sup>, expected for carbapatite, are not observed. The strong fluorescence background has been corrected on the presented spectra.





#### Table 1 Baseline clinical, biologic and histologic characteristics of the 36 CUA patients

| Characteristic                       | Value      |  |
|--------------------------------------|------------|--|
| Demographic                          |            |  |
| Female/male ratio                    | 2.6        |  |
| Age at diagnosis, years              | 64 [33–89] |  |
| Comorbidity                          |            |  |
| Dialysis                             | 30 (83%)   |  |
| Dialysis-to-CUA interval (months)    | 24 [1–156] |  |
| Diabetes                             | 23 (64%)   |  |
| Hypertension                         | 33 (92%)   |  |
| Body mass index $>30 \text{ kg/m}^2$ | 14 (39%)   |  |
| Vitamin K antagonists                | 16 (44%)   |  |
| Clinical                             |            |  |
| Proximal CUA                         | 10 (28%)   |  |

| Necrosis  | 26 (72%)         |  |  |  |
|---|------------------|--|--|--|
| Ulceration  | 24 (67%)         |  |  |  |
| Livedo reticularis  | 18 (50%)         |  |  |  |
| Indurated plaques   | 15 (42%)         |  |  |  |
| Nodular lesions   | 9 (25%)          |  |  |  |
| Biologic  |                  |  |  |  |
| Serum calcium, mmol/L   | 2.26 [1.89–2.84] |  |  |  |
| Serum phosphate, mmol/L   | 1.57 [0.93–3.68] |  |  |  |
| Calcium × phosphate product >4.5 mmol <sup>2</sup> /L <sup>2</sup>                        | 12 (33%)         |  |  |  |
| Serum parathormone >90 ng/L   | 24 (67%)         |  |  |  |
| Serum albumin (median), g/L   | 28 [18–37]       |  |  |  |
| Cutaneous histology   | 29               |  |  |  |
| Vascular calcifications   | 29 (100%)        |  |  |  |
| Interstitial calcifications   | 22 (76%)         |  |  |  |
| Thrombosis  | 5 (14%)          |  |  |  |
| Values are expressed as $n$ (%) or median [range], unless stated otherwise. CUA, calcific |                  |  |  |  |
| uremic arteriolopathy   |                  |  |  |  |

| 2 | 2 |
|---|---|
| 2 | э |